Pretreatment Modified Albumin-Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma.
Takashi TanakaKazuhide TakataKeiji YokoyamaHiromi FukudaRyo YamauchiAtsushi FukunagaSatoshi ShakadoShotaro SakisakaFumihito HiraiPublished in: Current oncology (Toronto, Ont.) (2022)
Pretreatment mALBI grades 1 and 2a were the important predictive factors associated with the therapeutic response and the therapeutic continuation of ATZ + BV for patients with u-HCC.